Phaseline

Companies › Beijing Inno Medicine

Beijing Inno Medicine: clinical trials, targets and expected readouts

1 active drug program in 2 registered trials: 2 Phase 2; Cardiovascular; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
YN001–Phase 2Atherosclerotic Cardiovascular Disease (ASCVD); AtherosclerosisDec 2026

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07311330YN001Phase 2Atherosclerotic Cardiovascular Disease (ASCVD)CardiovascularDec 2026
NCT07521007YN001Phase 2AtherosclerosisCardiovascularJul 2027

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

Nectero Medical Rohto Pharmaceutical Cell Biopeutics Resources Sdn Bhd TR Therapeutics Kerecis

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.